SUMMARY OF THE INVENTION
The compounds of the present invention are antagonists of the VLA-4 integrin ("very late antigen-4"; CD49d/CD29; or .alpha..sub.4.beta..sub.1), the .alpha..sub.4.beta..sub.7 integrin (LPAM-1 and .alpha..sub.4.beta..sub.p), and/or the .alpha..sub.9.beta..sub.1 integrin, and